- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT02362529
Biomarkers of Neuroinflammation and Anti-Inflammatory Treatments in Major Depressive Disorder
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Szczegółowy opis
There will be three Phases in the study. Only MDE subjects will be invited to continue to Phase 2 and 3. Subjects will be invited to continue to the subsequent Phase given they meet entry criteria described below:
Phase 1: The investigators will evaluate whether TSPO is elevated in individuals during a current MDE compared to healthy controls. Eligible participants will receive one [18F]FEPPA PET scan and one MRI scan. Other measures will include urine sample, blood samples for genetic and peripheral biomarker analysis, a neurocognitive battery, mood scales and questionnaires.
Phase 2: Participants who have elevated TSPO VT in Phase 1 and are agreeable to receiving minocycline will be invited to participate in Phase 2. Based on our previous results participants will be considered candidates for Phase 2 if TSPO VT ≥ 10.5 (HAB) or ≥8.5 (MAB) in any of the primary regions of interest (prefrontal cortex, anterior cingulate cortex or insula). Eligible participants will be invited to participate in a randomized, double blind, placebo controlled trial, to receive either minocycline or placebo. After the eight weeks of treatment, participants will receive one [18F]FEPPA PET scan. Other measures will include urine samples, blood samples, mood scales and questionnaires.
Phase 3: If, after the initial eight week treatment period with either minocycline or placebo, any participant continues to have depressive symptoms (17-item Hamilton Depression Rating Scale score ≥ 8) they will be invited to participate in an eight week open label trial of celecoxib. Participants not eligible for Phase 2 may also be invited to participate in Phase 3 directly from Phase 1.
Typ studiów
Zapisy (Oczekiwany)
Faza
- Wczesna faza 1
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Ontario
-
Toronto, Ontario, Kanada, M5T 1R8
- Centre for Addiction and Mental Health
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Group 1 - Current major depressive episode (MDE) secondary to MDD
Inclusion Criteria:
- good physical health with no active medical conditions
- non-cigarette smoking
- no past or current substance abuse or dependence
- negative urine pregnancy test at screening and scan days (for women)
- primary diagnosis of current major depressive episode (MDE) and major depressive disorder (MDD) verified by SCID for DSM IV
- score greater than 19 on the 17 item HDRS
- non-response to a clinical trial of at least one antidepressant given at appropriate clinical dose
- willing to take medication for the duration of the trial and has previously taken antidepressants for the duration of the trial
- presently taking an antidepressant at a standard clinical dose.
Exclusion Criteria:
- history of neurological illness or autoimmune disorders
- never taken a tricyclic antidepressant or an antidepressant that raises norepinephrine
- received treatment with electroconvulsive therapy or mechanical brain stimulation in the previous 6 months
- currently taking medication contraindicated or that may possibly interact with either minocycline or celecoxib
- known intolerance or allergy to minocycline, other tetracyclines, sulfonamides or NSAIDs
- taken diazepam or other benzodiazepine use within the past month, except for lorazepam and clonazepam
- use of anti-inflammatory drugs or tetracyclines lasting ≥1 week within the past month
- history of severe hepatic or renal insufficiency, asthma, allergies, gastrointestinal disease, ischemic heart disease, cerebrovascular disease or congestive heart failure
- lactose intolerance
Group 2 - Healthy Controls - Phase 1 (baseline scan) only
Inclusion criteria:
- score below 8 on the 17 item HDRS
- good physical health
- non-cigarette smoking
- negative urine pregnancy test at screening and scan days (for women)
- negative urine screen for drugs of abuse
Exclusion criteria:
- past or current diagnosis of axis I or axis II disorder as determined by the SCID I and SCID II for DSM IV
- history of psychotropic medication use
- history of neurological illness or autoimmune disorder
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Podstawowa nauka
- Przydział: Randomizowane
- Model interwencyjny: Zadanie dla jednej grupy
- Maskowanie: Poczwórny
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
---|---|
Eksperymentalny: Minocycline
The dose of minocycline would be 50mg per day on week 1, 50mg bid on week 2 and 100mg bid weeks 3-8.
For tapering, the dose will be reduced to 50mg bid for a week, and then stopped.
|
50 mg and 100 mg capsule, oral administration
Inne nazwy:
|
Komparator placebo: Placebo
The number and appearance of the pills would be identical to those in the minocycline arm.
|
Lactose monohydrate in identical gel capsules to minocycline, oral administration.
Inne nazwy:
|
Inny: Celecoxib
This will be an open label trial for those with Hamilton Depression Rating Scale score ≥ 8 following the minocycline v. placebo trial or those not eligible for Phase 2. Dose of celecoxib will be 100 mg bid for the first week and 200mg bid for weeks 2-8.
For tapering, the dose of celecoxib will be reduced to 100mg bid for one week, and then stopped.
|
100 mg and 200 mg capsules, oral administration.
Inne nazwy:
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Translocator total distribution volume (TSPO VT): Treatment Effect of Minocycline in MDE Subjects
Ramy czasowe: Pre- and post-minocycline or placebo treatment= 8 weeks total between pretreatment and posttreatment scans
|
TSPO VT will be measured using [18F]FEPPA positron emission tomography brain scans.
Eligible MDE participants will be randomized to either minocycline or placebo.
Following 8 weeks of either minocycline or placebo treatment, MDE participants will have a second PET scan .
|
Pre- and post-minocycline or placebo treatment= 8 weeks total between pretreatment and posttreatment scans
|
Translocator total distribution volume (TSPO VT): Difference between MDE and healthy subjects
Ramy czasowe: Pre-treatment scan will take place up to 8 weeks from initial assessment
|
Compare baseline TSPO VT prior to treatment between MDE group and healthy group
|
Pre-treatment scan will take place up to 8 weeks from initial assessment
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Change in Hamilton Depression Rating Scale Score
Ramy czasowe: Pre- and post-minocycline treatment (8 weeks total between pre- and post-treatment). Pre- and post-celecoxib treatment (8 weeks total between pre- and post-treatment).
|
Change in HDRS score following minocycline vs. placebo treatment.
Change in HDRS score following celecoxib treatment.
|
Pre- and post-minocycline treatment (8 weeks total between pre- and post-treatment). Pre- and post-celecoxib treatment (8 weeks total between pre- and post-treatment).
|
Inne miary wyników
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Hopkins Verbal Learning Test-Revised
Ramy czasowe: Pre- and post-minocycline or placebo treatment (8 weeks between pre- and post-treatment measure)
|
To assess verbal memory we will administer the Hopkins Verbal Learning Test-Revised to MDE participants before and after treatment.
|
Pre- and post-minocycline or placebo treatment (8 weeks between pre- and post-treatment measure)
|
Brief Visuospatial Memory Test-Revised
Ramy czasowe: Pre- and post-minocycline or placebo treatment (8 weeks between pre- and post-treatment measure)
|
To assess visuospatial memory we will administer the Brief Visuospatial Memory Test-Revised to MDE participants before and after treatment.
|
Pre- and post-minocycline or placebo treatment (8 weeks between pre- and post-treatment measure)
|
Comprehensive Trails Making Test
Ramy czasowe: Pre- and post-minocycline or placebo treatment.
|
To assess psychomotor speed and attention we will administer the Comprehensive Trails Making Test to MDE participants before and after treatment.
|
Pre- and post-minocycline or placebo treatment.
|
Genetic sample
Ramy czasowe: Phase 1-single sample
|
The priority of the genetic sample is to analyze the alleles of polymorphism rs6971 which has an association with the affinity of most second generation TSPO ligands including [18F]FEPPA.
The genetic sample will also be used to study sequences of genes that are believed to affect TSPO expression, inflammation, mood and conditions that may predispose to mood disorders.
|
Phase 1-single sample
|
Blood samples (serum and plasma)
Ramy czasowe: Pre- and post-minocycline or placebo treatment (8 weeks between measures). Pre- and post-celecoxib treatment (8 weeks between measures).
|
Analyses will include complete blood cell count (CBC), ESR, hepatic and renal function.
Peripheral marker analyses will include proteins related to TSPO expression and inflammation.
Plasma minocycline and celecoxib levels will be analyzed.
|
Pre- and post-minocycline or placebo treatment (8 weeks between measures). Pre- and post-celecoxib treatment (8 weeks between measures).
|
Współpracownicy i badacze
Śledczy
- Główny śledczy: Jeffrey H Meyer, MD, PhD, Centre for Addiction and Mental Health; University of Toronto
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Oszacować)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
- Objawy behawioralne
- Zaburzenia psychiczne
- Zaburzenia nastroju
- Depresja
- Zaburzenia depresyjne
- Zaburzenia depresyjne, majorze
- Fizjologiczne skutki leków
- Molekularne mechanizmy działania farmakologicznego
- Środki przeciwinfekcyjne
- Agenty obwodowego układu nerwowego
- Inhibitory enzymów
- Środki przeciwbólowe
- Agenci systemu sensorycznego
- Środki przeciwzapalne, niesteroidowe
- Środki przeciwbólowe, nie narkotyczne
- Środki przeciwzapalne
- Środki przeciwreumatyczne
- Inhibitory cyklooksygenazy
- Środki przeciwbakteryjne
- Inhibitory cyklooksygenazy 2
- Celekoksyb
- Minocyklina
Inne numery identyfikacyjne badania
- REB056/2014
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na Ciężkie zaburzenie depresyjne
-
CorrectSequence Therapeutics Co., LtdRekrutacyjnyBeta-talasemia majorChiny
-
First Affiliated Hospital of Guangxi Medical UniversityNieznany
-
Memorial Sloan Kettering Cancer CenterAktywny, nie rekrutującyPotwierdzona diagnoza ß-talasemii MajorStany Zjednoczone
-
bluebird bioZakończony
-
Aghia Sophia Children's Hospital of AthensNieznanyAsplenia | β-talasemia MajorGrecja
-
Jagannadha R AvasaralaZakończonyStwardnienie rozsiane | Zapalenie nerwu wzrokowego | Neuromyelitis Optica Spectrum Disorder Atak | Zapalenie nerwu wzrokowego i spektrum zaburzeń nerwu wzrokowego Nawrót | Neuromyelitis Optica Spectrum Disorder ProgresjaStany Zjednoczone
-
AstraZenecaOutcomes InsightsZakończonyPoważne krwawienie związane z antykoagulantamiStany Zjednoczone
-
BGI-researchShenzhen Children's HospitalJeszcze nie rekrutacja
-
National Institute of Allergy and Infectious Diseases...Zakończony
-
National Institute of Allergy and Infectious Diseases...ZakończonyVariola Major (ospa)Stany Zjednoczone